By researching and understanding cancer disease mechanisms, cancer survival rates have doubled over the past 40 years. Now, as genome editing technologies advance, there are research tools that can bring clarity to understanding and new discoveries in cancer with renewed vigour.
If you are using genome engineering to research cancer, join us in London to get an understanding of how this exciting new technology is being used and is advancing our understanding and treatment of cancer. You will hear how world leading cancer researchers and scientists developing cancer drugs are using CRISPR-Cas9 technologies in their pursuit of eradicating this disease.
We have experienced more interested than anticipated and are sorry that this event is now full.
If you register today you will be added to a waiting list and contacted prior to the event if a space becomes available.
|08:20–09:15||Registration, coffee & exhibition|
|09:30–10:00||Dr. Robin Ketteler—Group leader, University College London, London, UK|
Understanding autophagy signaling in cancer using CRISPR/Cas9 genome editing
|10:00–10:30||Dr. Maria Jose Martin—Senior Scientist, Immunocore Ltd, Oxford, UK|
Incorporating CRISPR into preclinical testing of bispecific TCR based biologics
|10:30–10:45||Jack Donaghy—Biomedical Sciences, Undergraduate Student, Ulster University, Northern Ireland, UK|
Design and in silico testing of genome editing tools and importance in cancer research, particularly Leukemia
|10:45–11:15||Coffee & exhibition|
|11:15–11:45||Nicolas Dumaz—Research Director, Skin Research Institute, Inserm, France|
PARKIN inactivation links Parkinson’s disease to melanoma
|11:45–12:15||Dr. Lorena Benedetti—Research Associate, King’s College London, London, UK|
A CRISPR approach to validate synthetic lethal interactions in cancer
|12:15–13:15||Lunch & exhibition|
|13:15–13:45||Xavier J. de Mollerat du Jeu—Director R&D Life Sciences, Thermo Fisher Scientific, Carlsbad, USA|
New delivery solutions for enabling CRISPR-based genome editing in physiologically relevant cell models and immune cells
|13:45–14:15||Dr Josephine Walton—Postdoctoral Researcher, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK|
CRISPR/Cas9 mediated Trp53, Brca1, Brca2, Pten and Nf1 knockout to generate improved preclinical models of ovarian high grade serous carcinoma
|14:15–14:45||Afternoon break and exhibition|
|14:45–15:15||Gavin Allsop (PhD)—Technical Sales specialist, Thermo Fisher Scientific, London, UK|
CRISPR/Cas9 protein for highly efficient and high throughput cell engineering applications
|15:15–15:45||Dr. Patrick O’Shea—Senior Scientist, AstraZeneca, Cambridge, UK|
CRISPR/Cas9 for Functional Genomics Case Study: Regulators of NF-kB signalling
|15:45–16:00||Wrap up & close|
|16:00–17:00||Poster session & exhibition|
Agenda is subject to change